Nature Communications (Sep 2022)
Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
- Andrew Poole,
- Vijaykumar Karuppiah,
- Annabelle Hartt,
- Jaafar N. Haidar,
- Sylvie Moureau,
- Tomasz Dobrzycki,
- Conor Hayes,
- Christopher Rowley,
- Jorge Dias,
- Stephen Harper,
- Keir Barnbrook,
- Miriam Hock,
- Charlotte Coles,
- Wei Yang,
- Milos Aleksic,
- Aimee Bence Lin,
- Ross Robinson,
- Joe D. Dukes,
- Nathaniel Liddy,
- Marc Van der Kamp,
- Gregory D. Plowman,
- Annelise Vuidepot,
- David K. Cole,
- Andrew D. Whale,
- Chandramouli Chillakuri
Affiliations
- Andrew Poole
- Immunocore Ltd.
- Vijaykumar Karuppiah
- Immunocore Ltd.
- Annabelle Hartt
- School of Biochemistry, University of Bristol, Biomedical Sciences Building, University Walk
- Jaafar N. Haidar
- Eli Lilly & Co, Lilly Corporate Center
- Sylvie Moureau
- Immunocore Ltd.
- Tomasz Dobrzycki
- Immunocore Ltd.
- Conor Hayes
- Immunocore Ltd.
- Christopher Rowley
- Immunocore Ltd.
- Jorge Dias
- Immunocore Ltd.
- Stephen Harper
- Immunocore Ltd.
- Keir Barnbrook
- Immunocore Ltd.
- Miriam Hock
- Immunocore Ltd.
- Charlotte Coles
- Immunocore Ltd.
- Wei Yang
- Eli Lilly & Co, Lilly Corporate Center
- Milos Aleksic
- Immunocore Ltd.
- Aimee Bence Lin
- Eli Lilly & Co, Lilly Corporate Center
- Ross Robinson
- Immunocore Ltd.
- Joe D. Dukes
- Immunocore Ltd.
- Nathaniel Liddy
- Immunocore Ltd.
- Marc Van der Kamp
- School of Biochemistry, University of Bristol, Biomedical Sciences Building, University Walk
- Gregory D. Plowman
- Eli Lilly & Co, Lilly Corporate Center
- Annelise Vuidepot
- Immunocore Ltd.
- David K. Cole
- Immunocore Ltd.
- Andrew D. Whale
- Immunocore Ltd.
- Chandramouli Chillakuri
- Immunocore Ltd.
- DOI
- https://doi.org/10.1038/s41467-022-32811-1
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
Cancers often harbor mutations in genes encoding important regulatory proteins, but therapeutic targeting of these molecules proves difficult due to their high structural similarity to their non-mutated counterpart. Here authors show the engineering of T cell engaging bispecific protein able to selectively target cancer cells with a high-frequency mutation in the KRAS oncogene.
